+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy

Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy

Aids 28(16): 2407-2415

Previous studies have shown that statins use is associated with a lower mortality risk or occurrence of non-Hodgkin's lymphoma or non-AIDS-defining malignancies (NADMs) in HIV-positive patients. We evaluated the effect of statin therapy on the occurrence of all AIDS-defining malignancy (ADM) and NADM among HIV-positive patients. A chart study on HIV-1 infected patients attending the Infectious Diseases Department of the San Raffaele Scientific Institute, Italy. Incident malignancies diagnosed since antiretroviral treatment (ART) initiation until October 2012 among treated patients not taking statins at ART initiation. Statin therapy had to precede cancer diagnosis, if it occurred. Malignancies that occurred before ART or statin initiation were excluded. Follow-up was calculated since ART initiation until the first cancer diagnosis or loss to follow-up or death or last available visit, whichever occurred first. Results are described as median (interquartile range, IQR). Five thousand, three hundred and fifty-seven HIV-1 treated patients were included. During 52 663 person-years, 740 (14%) patients had a history of statin use; 375 malignancies occurred: 12 (1.6%) malignancies (0 ADM; 12 NADM, crude incidence rate, 1.3/1000 person-years) among statin users and 363 (7.9%) malignancies (194 ADM; 169 NADM, crude incidence rate, 8.4/1000 person-years) among non-statin users. By multivariate Fine-Gray regression, statin use was associated with a lower risk of cancer [adjusted hazard ratio (95% confidence interval) for ever use: 0.45 (0.17-0.71)]. Among HIV-1 treated patients, statin use was associated with a lower risk of cancer; the benefit was mainly related to AIDS-defining malignancies. Confirmatory studies are needed to consider the residual confounding likely present in this study.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 056803914

Download citation: RISBibTeXText

PMID: 25160933

DOI: 10.1097/qad.0000000000000443

Related references

Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clinical Infectious Diseases 52(12): 1458-1465, 2011

Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States. Aids Patient Care and Stds 24(5): 279-286, 2010

AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Current Opinion in Oncology 19(5): 446-451, 2007

Short Communication: HIV RNA Levels Predict AIDS-Defining and Non-AIDS-Defining Cancers After Antiretroviral Therapy Initiation Among HIV-Infected Adults. Aids Research and Human Retroviruses 31(5): 514-518, 2016

Non-AIDS-defining malignancies among HIV-infected patients in the highly active antiretroviral therapy era. Current Hiv/Aids Reports 5(3): 140-149, 2008

Risk of deaths, AIDS-defining and non-AIDS defining events among Ghanaians on long-term combination antiretroviral therapy. Plos One 9(10): E111400, 2016

Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clinical Infectious Diseases 39(9): 1380-1384, 2004

Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy. HIV Medicine 16(5): 265-272, 2015

Incidence and risk factors of non AIDS-defining as compared with AIDS-defining infections and cancers in a cohort of HIV-infected patients initiating a protease inhibitor -containing regimen. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 320, 2001

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clinical Infectious Diseases 48(8): 1138-1151, 2009

Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition. Clinical Infectious Diseases 54(6): 853-861, 2012

Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era. Aids Research and Human Retroviruses 29(8): 1097-1104, 2013

AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy. Ethnicity and Disease 18(2 Suppl 2): S2-189-94, 2008

Malignancies not included among AIDS-defining disorders, in the era of highly active antiretroviral therapy. Recenti Progressi in Medicina 100(12): 547-549, 2010

Non-aids defining malignancies in patients infected with HIV. Proceedings of the American Association for Cancer Research Annual Meeting (41): 759-760, 2000